公开(公告)号：US20180155695A1

公开(公告)日：2018-06-07

申请号：US15523571

申请日：2015-03-30

Applicant: Masakazu Kurita

Inventor： Masakazu Kurita

IPC: C12N5/10 ,  A61K35/12 ,  A01K67/027 ,  C12N15/09

CPC classification number: C12N5/10 ,  A01K67/027 ,  A61K35/12 ,  A61K48/00 ,  C12M1/00 ,  C12N5/0625 ,  C12N5/0656 ,  C12N15/00 ,  C12N15/09 ,  C12N2506/1307 ,  C12N2510/00 ,  C12N2740/16043 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  G01N33/5005 ,  G01N33/5082

Abstract: To convert directly from a somatic cell into a cell having the ability to form stratified epithelial tissue that can act as outer skin of the body, a method for producing a cell having the ability to form stratified epithelial tissue is provided, the method including the step of introducing into a somatic cell at least one gene expressed relatively strongly in a cell having the ability to form stratified epithelial tissue.

公开(公告)号：US20180140635A1

公开(公告)日：2018-05-24

申请号：US15865055

申请日：2018-01-08

Applicant: Precision BioSciences, Inc.

Inventor： Derek Jantz ,  James Jefferson Smith ,  Michael G. Nicholson ,  Daniel T. MacLeod ,  Jeyaraj Antony ,  Victor Bartsevich

IPC: A61K35/17 ,  A61K39/00 ,  A61K48/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/09 ,  C12N15/113 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61K48/0008 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/70503 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/53 ,  C07K2319/01 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/74 ,  C12N5/0636 ,  C12N15/09 ,  C12N15/113 ,  C12N15/86 ,  C12N2510/00

Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.

公开(公告)号：US20180134786A1

公开(公告)日：2018-05-17

申请号：US15549923

申请日：2016-02-12

Applicant: Tohoku University

Inventor： Yukinari Kato ,  Mika Kaneko ,  Satoshi Ogasawara

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/28 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/705

Abstract: The present invention provides a method for producing an antibody against podocalyxin expressed specifically in cancer cells. The method includes a step of introducing a nucleic acid encoding all or a portion of podocalyxin into cells expressing a cancer cell-specific sugar chain structure to cause cancer cell-specific podocalyxin or a portion thereof to be expressed therein, a step of immunizing a non-human mammal with the cancer cell-specific podocalyxin or portion thereof to obtain antibodies, and a step of purifying the antibodies by primary screening using purified cancer cell-specific podocalyxin or a portion thereof.

公开(公告)号：US20180133254A1

公开(公告)日：2018-05-17

申请号：US15864947

申请日：2018-01-08

Applicant: Precision BioSciences, Inc.

Inventor： Derek Jantz ,  James Jefferson Smith ,  Michael G. Nicholson ,  Daniel T. MacLeod ,  Jeyaraj Antony ,  Victor Bartsevich

IPC: A61K35/17 ,  C07K16/30 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C12N15/86 ,  C12N15/113 ,  C12N15/09 ,  C12N5/0783 ,  A61K48/00

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61K48/0008 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/70503 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/53 ,  C07K2319/01 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/74 ,  C12N5/0636 ,  C12N15/09 ,  C12N15/113 ,  C12N15/86 ,  C12N2510/00

Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.

公开(公告)号：US20180127814A1

公开(公告)日：2018-05-10

申请号：US15691337

申请日：2017-08-30

Applicant: Kabushiki Kaisha Toshiba

Inventor： Koji HASHIMOTO ,  Keiko Ito ,  Mika Inada

IPC: C12Q1/68

CPC classification number: C12Q1/6837 ,  C12N15/09 ,  C12Q1/6823 ,  C12Q1/6825 ,  C12Q1/6851 ,  C12Q2525/301 ,  C12Q2527/101 ,  C12Q2537/1373 ,  C12Q2537/163 ,  C12Q2563/113 ,  C12Q2531/101

Abstract: According to one embodiment, a method for detecting target nucleic acid includes the following steps. (A) A reaction field is formed by placing a reaction mixture on an electrode, and the reaction mixture contains the sample, a primer set, an amplification enzyme, 4 mM to 30 mM of magnesium ion, and a redox probe. The redox probe has an oxidation reduction potential, which generates an electric signal of which amplitude increases. (B) The reaction field is maintained under an amplification reaction condition. (C) The electric signal is detected with the electrode. (D) Existence or quantity of the target nucleic acid is determined.

公开(公告)号：US09944596B2

公开(公告)日：2018-04-17

申请号：US15518782

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Takahiko Taniguchi ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: C07D207/08 ,  A61K31/401

CPC classification number: C07D207/08 ,  A61K31/40 ,  A61K31/401 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US20180099996A1

公开(公告)日：2018-04-12

申请号：US15634926

申请日：2017-06-27

Applicant: Base Pair Biotechnologies, Inc.

Inventor： George W. Jackson

IPC: C07K14/00

CPC classification number: C07K14/00 ,  C07C69/80 ,  C07K2317/32 ,  C12N15/09 ,  C12N15/115 ,  C12N2310/16

Abstract: This invention relates to functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, more particularly to functional ligands with binding affinity to target molecules, and further particularly to functional ligands with binding affinity to phthalates, such as DEHP.

公开(公告)号：US09931373B2

公开(公告)日：2018-04-03

申请号：US14561573

申请日：2014-12-05

Applicant: Igor Dudich ,  Lydia Semenkova ,  Igor Dudich ,  Eduard Tatulov

Inventor： Elena Dudich ,  Lydia Semenkova ,  Igor Dudich ,  Eduard Tatulov

IPC: C07K14/475 ,  C12N1/16 ,  C12N1/19 ,  C12N15/10 ,  C12N15/81 ,  C12N15/09 ,  C12P21/02 ,  A61K38/17 ,  A61K33/24 ,  A61K45/06 ,  C07K14/47 ,  A61K8/64 ,  A61Q19/08 ,  C12N5/09 ,  C12N5/10

CPC classification number: A61K38/1709 ,  A61K8/64 ,  A61K33/24 ,  A61K38/17 ,  A61K45/06 ,  A61Q19/08 ,  C07K14/47 ,  C07K14/4715 ,  C12N1/16 ,  C12N5/0693 ,  C12N5/10 ,  C12N15/09 ,  C12N15/81 ,  C12P21/02 ,  A61K2300/00

Abstract: Disclosed are pharmaceutical and synergistic compositions human recombinant alpha-fetoprotein expressed in eukaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy, and cosmetology and also for the diagnosis of cancer and embryogenic pathologies.

公开(公告)号：US20180086835A1

公开(公告)日：2018-03-29

申请号：US15818861

申请日：2017-11-21

Applicant: Glaxo Group Limited

Inventor： Andrew Beaton ,  Caroline Dimech ,  Peter Franz Ertl ,  Susannah Karen Ford ,  Ruth Mcadam

IPC: C07K16/28 ,  C12N15/09 ,  C12N1/00

CPC classification number: C07K16/2863 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C12N1/00 ,  C12N15/09

Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.

公开(公告)号：US20180079723A1

公开(公告)日：2018-03-22

申请号：US15563128

申请日：2016-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Ryo Mizojiri ,  Moriteru ASANO ,  Daisuke TOMITA ,  Hiroshi BANNO ,  Michiko TAWADA ,  Noriyuki NII ,  Krista E. GIPSON ,  Hironobu MAEZAKI ,  Shuntaro TSUCHIYA ,  Mayumi IMAI ,  Yuichiro AMANO

IPC: C07D213/65 ,  C07C233/25 ,  C07D401/12 ,  C07C255/54 ,  C07D213/69 ,  C07C233/18 ,  C07D263/42 ,  C07D263/32 ,  C07D413/04 ,  C07D239/34 ,  C07D241/18 ,  C07D277/34 ,  C07D231/12 ,  C07D207/12 ,  C07D261/08 ,  C07D417/04 ,  C07D237/14 ,  C07D211/46 ,  C07D213/74 ,  C07D213/81

CPC classification number: C07D213/65 ,  A61K31/165 ,  A61K31/167 ,  A61K31/277 ,  A61K31/381 ,  A61K31/402 ,  A61K31/415 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  C07C233/18 ,  C07C233/25 ,  C07C233/47 ,  C07C255/54 ,  C07C2601/02 ,  C07C2601/14 ,  C07D207/08 ,  C07D207/12 ,  C07D211/44 ,  C07D211/46 ,  C07D213/643 ,  C07D213/69 ,  C07D213/74 ,  C07D213/75 ,  C07D213/81 ,  C07D231/12 ,  C07D237/14 ,  C07D239/34 ,  C07D241/18 ,  C07D261/08 ,  C07D263/32 ,  C07D263/42 ,  C07D277/34 ,  C07D333/20 ,  C07D401/04 ,  C07D401/12 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C12N9/99 ,  C12N15/09

Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.